The IBTA’s monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.
You can also read the IBTA e-News February 2022 edition in full online here.
Some of the highlights from this month’s round-up:
- The IBTA and leading neuro-oncology societies have issued a joint statement on the current crisis in Ukraine.
- March is Brain Tumour Awareness Month in the United Kingdom when there will be a programme of various activities organised by charities and not-for-profits to highlight the unmet needs of the brain tumour community.
- A summary for clinicians of the 2021 Central Brain Tumor Registry of the United States annual report has been published in Neuro-Oncology Practice.
- A statistical analysis that combines the results of several scientific studies has found that the widely used drug cyproterone acetate (CPA) may contribute to the growth of meningioma brain tumours.
- A case report in the journal Epilepsy & Behavior Reports details the use of an IDH1 inhibitor to prevent seizures in a patient with IDH1 mutant oligodendroglioma. The report says that seizure frequency was markedly reduced after starting the IDH1 inhibitor, ivosidenib, in the absence of any changes to traditional anti-seizure medications.
- A panel of experts assembled by The College of American Pathologists has developed new guidelines to improve the clinical care of patients diagnosed with diffuse glioma.
- A review in the journal Neuro-Oncology Practice analysing data on 1,133 patients with pineoblastoma from 2000-2017 from the Central Brain Tumor Registry of the United States has revealed that the incidence of this rare malignant brain tumour is highest in black children and adults.
- Results of a 76-patient recurrent glioblastoma trial published in the journal Clinical Cancer Research has shown that selinexor (the first in a new class of anti-cancer drugs) was able to shrink brain tumours at therapeutic doses without serious side effects.
- A study published in the Journal of Clinical Neuroscience in a single centre in the Philippines has revealed that glioblastoma patients often presented at an advanced stage of disease and a majority (62%) did not receive additional treatment after neurosurgery.
- A review in the Journal of Translational Medicine has investigated studies that look at the entire DNA sequence of tumours, termed genome-wide association studies (GWAS), to examine the potential of repurposing US Food and Drug Administration (FDA) approved antipsychotics for glioblastoma. The study identified 12 candidate drugs.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.
